Court Makes It Clear: Rule Requiring Copay Assistance to Count Now in Effect

“We thank the Court for siding, yet again, with patients who struggle to afford their prescription drugs and rely on copay assistance. The Court has clarified what we have been asserting: the rule that states copay assistance must count is in effect. Now, that clear rule must be followed by insurers.”

House Proposes to Gut Ending HIV Programs

“While we appreciate the sustained funding for some domestic HIV and hepatitis programs, we are devastated by the proposal to eliminate the Ending the HIV Epidemic initiative,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “We were on a trajectory to end HIV by ensuring all people have access to care and treatment, and prevent new infections through increasing access to PrEP, but now all those efforts will be lost. This bill cannot stand as is.”

25 HIV & Hepatitis Organizations File Amicus Brief to Protect Preventive Services Coverage

The HIV+Hepatitis Policy Institute and 24 other HIV and hepatitis organizations filed an amicus brief in support of the U.S. government in Braidwood Management v. Becerra, the challenge to the ACA’s preventive services coverage requirement, arguing, “A wholesale invalidation of the coverage requirement for USPSTF’s recommendations would strike a critical, unnecessary, and costly blow to the battle to end HIV, hepatitis, and other infectious diseases.”

HIV+Hep releases report detailing funding needed to increase PrEP uptake

The HIV+Hepatitis Policy Institute has released a report modeling the resources needed to fund a national PrEP program to cover the cost of medications, associated labs, and prescriber time for the uninsured along with necessary provider and community outreach to increase uptake, estimating the cost at $521 million for the first year and $6.18 billion over ten years.

Nation Must Do Better in Ensuring Patients Receive Hepatitis C Curative Drugs

"This situation is completely unacceptable. We have a cure for a serious infectious disease, but people who have taken the time to get tested and know they have hepatitis C are not being cured," commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. "The vast majority of these people have health coverage but payers such as private insurers, state Medicaid programs, and Medicare are erecting barriers to patient access."

Who We Are

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Key Issues

Causes We Care About, and So Should You!


Promote necessary funding, programs, and policies to end the HIV epidemic in the United States


Promote necessary funding, programs, and policies to end viral hepatitis in the United States


Promote necessary funding, programs, and policies to end viral hepatitis in the United States

Facebook posts by @HIV+Hep ... See MoreSee Less
View on Facebook
Blue Cross Blue Shield NC customers now pay less for HIV drugs. Those drugs are no longer on the highest priced tier, ending discrimination inquiry: ... See MoreSee Less
View on Facebook

Tweets by @HIV+Hep

Pin It on Pinterest